ArticleNature communications2026
Modelling impacts of paediatric amoxicillin shortage management on pneumococcal resistance and invasive disease in Europe.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic shortages are increasing worldwide. Their impact on individual health and bacterial ecology is unknown, but it could be significant, and there is a lack of epidemiological evidence. Here, we assess the impact of beta-lactam shortage management on pneumococcal resistance and the incidence of invasive pneumococcal disease (IPD). We developed a mechanistic model of S. pneumoniae paediatric colonization and transmission, accounting for beta-lactam and macrolide exposure. We explored the effects of four antibiotic allocation strategies following a one-year beta-lactam shortage: lowering consumption frequency, shortening treatment duration, reducing the daily dose, or substituting beta-lactams with macrolides. These strategies were analyzed in different European pharmaco-epidemiological settings. We found heterogeneous impacts of allocation strategies, amplified at high shortage intensity. The adverse outcomes of shortages increased with baseline antibiotic consumption and the main determinants of the optimal strategy were the initial prevalence of resistance. Reducing beta-lactam frequency most effectively limited resistance, lowering penicillin-non-susceptible and multidrug-resistant strains by up to 21% in Spain during a 50% shortage. The optimal strategy for minimizing IPD incidence was country-dependent: either lowering the daily dose or beta-lactam-to-macrolide substitution. However, the latter significantly increased macrolide resistance, reaching up to 26.2% in Denmark, for a 50% shortage. Our results show that public health priorities and country-specific pharmaco-epidemiological factors should guide antibiotic management strategies during antimicrobial shortages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.